In Guanacaste, one dose of the bivalent HPV vaccine in 620 girls gave antibody levels non-inferior to three quadrivalent doses in women for HPV 18 but not HPV 16, though almost every girl had antibodies to both after three years.
A non-randomised, open-label immunobridging trial in Guanacaste Province (NCT03728881) that gave one dose of bivalent HPV vaccine to girls aged 9 to 14 and three doses of quadrivalent vaccine to women aged 18 to 25, and compared antibody concentrations at 36 months, to support a single-dose indication for the bivalent vaccine. Funded by the National Cancer Institute, Cancer Research UK and the Gates Foundation.
Antibody levels alone did not meet the bar for changing the vaccine's label to one dose, which is why trials measuring protection directly, such as ESCUDDO, were needed.
Shares Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA (ACIB-FUNIN), HPV bivalent vaccine (types 16 and 18), National Cancer Institute (NIH), Cervical cancer.
Shares Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA (ACIB-FUNIN), HPV bivalent vaccine (types 16 and 18), National Cancer Institute (NIH), Cervical cancer.
Shares HPV bivalent vaccine (types 16 and 18), Cervical cancer.
Shares HPV bivalent vaccine (types 16 and 18), Cervical cancer.
Shares Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA (ACIB-FUNIN), Cervical cancer.
Shares HPV bivalent vaccine (types 16 and 18), Cervical cancer.
Shares Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA (ACIB-FUNIN), Cervical cancer.
Shares Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA (ACIB-FUNIN), HPV bivalent vaccine (types 16 and 18), Cervical cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/